Patents by Inventor Louis A. Matis
Louis A. Matis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210246219Abstract: The disclosure provides compositions and methods for treating previously treated specific HER2-positive advanced or metastatic solid tumors. The disclosure provides compositions and methods for enhancing immune response in an individual having HER2-positive advanced or metastatic solid tumors. The method comprises administering a PD-laxis inhibitor and a bispecific agent that targets CD137 and HER2.Type: ApplicationFiled: August 27, 2019Publication date: August 12, 2021Inventors: Ingmar Bruns, Louis Matis, Shane Olwill, Thomas Jaquin
-
Patent number: 7405279Abstract: Novel chimeric fusion proteins comprising immunodominant epitopes of GAD and insulin are provided. Also provided are immunomodulatory methods for the use of such proteins for both the prevention and treatment of Type 1 diabetes mellitus. The chimeric fusion proteins of the invention are useful in predicting risk of onset of Type 1 diabetes, determining prognosis of Type 1 diabetes patients early in disease progression, and in evaluating patients for suitability as recipients of transplants of pancreatic cells or tissues. The administration of the proteins of the invention in accordance with the immunomodulatory methods of the invention results in beneficial effects on disease development and severity in patients suffering from or predicted to be at risk of developing Type 1 diabetes, as well as on the outcome of transplants of pancreatic cells or tissues in Type 1 diabetes patients.Type: GrantFiled: June 3, 2005Date of Patent: July 29, 2008Assignee: Alexion Pharmaceuticals, Inc.Inventors: Yi Wang, John Mueller, Louis A. Matis
-
Patent number: 7384915Abstract: Novel chimeric fusion proteins comprising immunodominant epitopes of GAD and insulin are provided. Also provided are immunomodulatory methods for the use of such proteins for both the prevention and treatment of Type 1 diabetes mellitus. The chimeric fusion proteins of the invention are useful in predicting risk of onset of Type I diabetes, determining prognosis of Type 1 diabetes patients early in disease progression, and in evaluating patients for suitability as recipients of transplants of pancreatic cells or tissues. The administration of the proteins of the invention in accordance with the immunomodulatory methods of the invention results in beneficial effects on disease development and severity in patients suffering from or predicted to be at risk of developing Type 1 diabetes, as well as on the outcome of transplants of pancreatic cells or tissues in Type I diabetes patients.Type: GrantFiled: June 3, 2005Date of Patent: June 10, 2008Assignee: Alexion Pharmaceuticals, Inc.Inventors: Yi Wang, John Mueller, Louis A. Matis
-
Patent number: 7279158Abstract: The use of compounds that block complement component C5 or its active fragments C5a and/or C5b (such compounds collectively referred to as “C5 blockers”) to treat established joint inflammation (arthritis) is disclosed. Administration of such C5 blockers has been found to: 1) arrest and/or reduce inflammation in joints which are already inflamed, and 2) inhibit the spread of inflammation to unaffected joints.Type: GrantFiled: January 5, 2005Date of Patent: October 9, 2007Assignee: Alexion Pharmaceuticals, Inc.Inventors: Yi Wang, Louis Matis
-
Patent number: 7041503Abstract: Compositions and methods are provided for the clinical assessment, diagnosis, and treatment of multiple sclerosis. The compositions of the invention are molecules related to the 21.5 kDa fetal isoform of human myelin basic protein, and include nucleic acids and polypeptides. The nucleic acid molecules of the invention are useful in the efficient production of modified and unmodified 21.5 kDa myelin basic protein polypeptides, such polypeptides being useful for assaying T cells for responsiveness to myelin basic protein epitopes. The polypeptides of the invention are also useful as therapeutic agents that act by inducing T cell responses, including apoptosis, as a means of treating multiple sclerosis.Type: GrantFiled: May 2, 1995Date of Patent: May 9, 2006Assignees: The United States of America as represented by the Department of Health and Human Services, Alexion Pharmaceuticals, Inc.Inventors: Steven H. Nye, Michael J. Lenardo, Henry F. McFarland, Louis A. Matis, Eileen Elliott Mueller, John P. Mueller, Clara M. Pelfrey, Stephen P. Squinto, James A. Wilkins
-
Publication number: 20060057678Abstract: Novel chimeric fusion proteins comprising immunodominant epitopes of GAD and insulin are provided. Also provided are immunomodulatory methods for the use of such proteins for both the prevention and treatment of Type 1 diabetes mellitus. The chimeric fusion proteins of the invention are useful in predicting risk of onset of Type I diabetes, determining prognosis of Type 1 diabetes patients early in disease progression, and in evaluating patients for suitability as recipients of transplants of pancreatic cells or tissues. The administration of the proteins of the invention in accordance with the immunomodulatory methods of the invention results in beneficial effects on disease development and severity in patients suffering from or predicted to be at risk of developing Type 1 diabetes, as well as on the outcome of transplants of pancreatic cells or tissues in Type I diabetes patients.Type: ApplicationFiled: June 3, 2005Publication date: March 16, 2006Applicant: Alexion Pharmaceuticals, Inc.Inventors: Yi Wang, John Mueller, Louis Matis
-
Publication number: 20060052581Abstract: Novel chimeric fusion proteins comprising immunodominant epitopes of GAD and insulin are provided. Also provided are immunomodulatory methods for the use of such proteins for both the prevention and treatment of Type 1 diabetes mellitus. The chimeric fusion proteins of the invention are useful in predicting risk of onset of Type I diabetes, determining prognosis of Type 1 diabetes patients early in disease progression, and in evaluating patients for suitability as recipients of transplants of pancreatic cells or tissues.Type: ApplicationFiled: June 3, 2005Publication date: March 9, 2006Applicant: Alexion Pharmaceuticals, Inc.Inventors: Yi Wang, John Mueller, Louis Matis
-
Publication number: 20060052580Abstract: Novel chimeric fusion proteins comprising immunodominant epitopes of GAD and insulin are provided. Also provided are immunomodulatory methods for the use of such proteins for both the prevention and treatment of Type 1 diabetes mellitus. The chimeric fusion proteins of the invention are useful in predicting risk of onset of Type I diabetes, determining prognosis of Type 1 diabetes patients early in disease progression, and in evaluating patients for suitability as recipients of transplants of pancreatic cells or tissues. The administration of the proteins of the invention in accordance with the immunomodulatory methods of the invention results in beneficial effects on disease development and severity in patients suffering from or predicted to be at risk of developing Type 1 diabetes, as well as on the outcome of transplants of pancreatic cells or tissues in Type I diabetes patients.Type: ApplicationFiled: June 3, 2005Publication date: March 9, 2006Applicant: Alexion Pharmaceuticals, Inc.Inventors: Yi Wang, John Mueller, Louis Matis
-
Patent number: 6982323Abstract: Novel chimeric fusion proteins comprising immunodominant epitopes of GAD and insulin are provided. Also provided are immunomodulatory methods for the use of such proteins for both the prevention and treatment of Type 1 diabetes mellitus. The chimeric fusion proteins of the invention are useful in predicting risk of onset of Type 1 diabetes, determining prognosis of Type 1 diabetes patients early in disease progression, and in evaluating patients for suitability as recipients of transplants of pancreatic cells or tissues. The administration of the proteins of the invention in accordance with the immunomodulatory methods of the invention results in beneficial effects on disease development and severity in patients suffering from or predicted to be at risk of developing Type 1 diabetes, as well as on the outcome of transplants of pancreatic cells or tissues in Type 1 diabetes patients.Type: GrantFiled: March 21, 2000Date of Patent: January 3, 2006Assignee: Alexion Pharmaceuticals, Inc.Inventors: Yi Wang, John Mueller, Louis A. Matis
-
Publication number: 20050226870Abstract: The use of compounds that block complement component C5 or its active fragments C5a and/or C5b (such compounds collectively referred to as “C5 blockers”) to treat established joint inflammation (arthritis) is disclosed. Administration of such C5 blockers has been found to: 1) arrest and/or reduce inflammation in joints which are already inflamed, and 2) inhibit the spread of inflammation to unaffected joints.Type: ApplicationFiled: January 5, 2005Publication date: October 13, 2005Applicant: Alexion Pharmaceuticals, Inc.Inventors: Yi Wang, Louis Matis
-
Publication number: 20040180808Abstract: Compositions and methods are provided for the clinical assessment, diagnosis, and treatment of multiple sclerosis. The compositions of the invention are molecules related to the 21.5 kDa fetal isoform of human myelin basic protein, and include nucleic acids and polypeptides. The nucleic acid molecules of the invention are useful in the efficient production of modified and unmodified 21.5 kDa myelin basic protein polypeptides, such polypeptides being useful for assaying T cells for responsiveness to myelin basic protein epitopes. The polypeptides of the invention are also useful as therapeutic agents that act by inducing T cell responses, including apoptosis, as a means of treating multiple sclerosis.Type: ApplicationFiled: May 2, 1995Publication date: September 16, 2004Inventors: STEVEN H. NYE, MICHAEL J. LENARDO, HENRY F. MCFARLAND, LOUIS A. MATIS, EILEEN E. MUELLER, JOHN P. MUELLER, CLARA M. PELFREY, STEPHEN P. SQUINTO, JAMES A. WILKINS
-
Publication number: 20030175267Abstract: The use of compounds that block complement component or its active fragments C5a and/or C5b (such compounds collectively referred to as “C5 blockers”) to treat established joint inflammation (arthritis) is disclosed. Administration of such C5 blockers has been found to: 1) arrest and/or reduce inflammation in joints which are already inflamed, and 2) inhibit the spread of inflammation to unaffected joints.Type: ApplicationFiled: June 2, 1997Publication date: September 18, 2003Inventors: YI WANG, LOUIS MATIS
-
Patent number: 6355245Abstract: The use of anti-C5 antibodies, e.g., monoclonal antibodies, to treat glomerulonephritis (GN) is disclosed. The administration of such antibodies at low dosage levels has been found to significantly reduce glomerular inflammation/enlargement and other pathologic conditions associated with GN. Also disclosed are anti-C5 antibodies and anti-C5 antibody-encoding nucleic acid molecules. These antibodies are useful in the treatment of GN and other inflammatory conditions involving pathologic activation of the complement system.Type: GrantFiled: June 7, 1995Date of Patent: March 12, 2002Assignee: Alexion Pharmaceuticals, Inc.Inventors: Mark J. Evans, Louis A. Matis, Eileen Elliott Mueller, Steven H. Nye, Scott Rollins, Russell P. Rother, Jeremy P. Springhorn, Stephen P. Squinto, Thomas C. Thomas, James A. Wilkins
-
Patent number: 6074642Abstract: The use of anti-C5 antibodies, e.g., monoclonal antibodies, to treat glomerulonephritis (GN) is disclosed. The administration of such antibodies at low dosage levels has been found to significantly reduce glomerular inflammation/enlargement and other pathologic conditions associated with GN.Type: GrantFiled: May 2, 1994Date of Patent: June 13, 2000Assignee: Alexion Pharmaceuticals, Inc.Inventors: Yi Wang, Louis Matis, Scott Rollins
-
Patent number: 6040428Abstract: A porcine E-selectin protein, its amino acid sequence, the sequence of a cDNA encoding the protein, antibodies reactive with the protein, and methods for the use of these molecules are disclosed. The molecules are used to diagnose the rejection of xenotransplanted pig organs, as well as to prevent and treat such transplant rejection.Type: GrantFiled: March 25, 1999Date of Patent: March 21, 2000Assignee: Alexion Pharmaceuticals, Inc.Inventors: Scott Rollins, Russell P. Rother, Louis A. Matis, Mark J. Evans
-
Patent number: 5891645Abstract: A porcine E-selectin protein, its amino acid sequence, the sequence of a cDNA encoding the protein, antibodies reactive with the protein, and methods for the use of these molecules are disclosed. The molecules are used to diagnose the rejection of xenotransplanted pig organs, as well as to prevent and treat such transplant rejection.Type: GrantFiled: June 1, 1994Date of Patent: April 6, 1999Assignee: Alexion Pharmaceuticals, Inc.Inventors: Scott Rollins, Russell P. Rother, Louis A. Matis, Mark J. Evans